Corpus Intelligence IC Memo — ST CHARLES MADRAS 2026-04-26 06:41 UTC
IC Memo — ST CHARLES MADRAS
Investment Committee Memorandum | OR | 24 beds | Grade C | EBITDA uplift $3.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST CHARLES MADRAS

CCN 381324 | JEFFERSON, OR | 24 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST CHARLES MADRAS is a 24-bed suburban community hospital in JEFFERSON, OR with $52.6M in net patient revenue and a 16.9% operating margin. The hospital serves a payer mix of 33.9% Medicare, 13.7% Medicaid, and 52.4% commercial.

Thesis: Turnaround. Our ML models identify $3.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 16.9% to 24.2% (+736bps).

Net Revenue HCRIS$52.6M
Current EBITDA COMPUTED$8.9M
Operating Margin COMPUTED16.9%
Occupancy HCRIS44.3%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS54.5%
Distress Probability ML53.1%

2. Market Context & Competitive Position

63
OR Hospitals
-8.1%
State Median Margin
33
Comparable Hospitals

OR has 63 Medicare-certified hospitals with a median operating margin of -8.1%. The target's margin of 16.9% places it above the state median. Among 33 size-comparable peers (12-48 beds), the median margin is -6.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-48), prioritizing same-state peers. 33 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST CHARLES MADRAS (Target)OR24$52.6M16.9%
GOOD SHEPHERD MEDICAL CENTEROR25$177.5M5.3%
COLUMBIA MEMORIAL HOSPITALOR25$165.9M5.2%
SAMARITAN LEBANON COMM HOSPITAOR25$157.9M3.9%
PROVIDENCE NEWBERG MEDICAL CENOR40$151.5M10.0%
SAMARITAN PACIFIC COMM HOSPITAOR25$141.7M3.7%
GRANDE RONDE HOSPITALOR25$134.8M-4.1%
PROVIDENCE MILWAUKIE HOSPITALOR40$128.8M-9.6%
MID-COLUMBIA MEDICAL CENTEROR44$123.2M-20.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.1M+210bp18mo
Cost to Collect4.5%2.5%$1.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$641K+122bp9mo
Clean Claim Rate88.0%96.0%$34K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.1M
Cost to Collect
$1.1M
Denial Rate Reduction
$1.0M
A/R Days Reduction
$641K
Clean Claim Rate
$34K
Total EBITDA Uplift$3.9M
Current EBITDA$8.9M
+ RCM Uplift+$3.9M
Pro Forma EBITDA$12.7M
Current Margin16.9%
Pro Forma Margin24.2%
WC Released (1x)$2.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$13.6M$97.3M7.13x48.1%
Base (11x exit)10.0x11.0x$13.6M$111.4M8.16x52.2%
Bull Case9.0x11.0x$12.3M$128.7M10.47x60.0%
Bull (12x exit)9.0x12.0x$12.3M$144.0M11.72x63.6%
Bear Case11.0x10.0x$15.0M$73.5M4.89x37.4%
Bear (11x exit)11.0x11.0x$15.0M$85.7M5.71x41.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 53.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 33 hospitals with 12-48 beds
  • Same-state prioritization (n=34)
  • Comp margins: P25=-16.1% / P50=-6.3% / P75=3.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.